In Part 2 of the ‘Optimizing Dosing Strategy for Late-Line Therapies in mCRC’ roundtable discussion, Drs. Grothey, Bekaii-Saab, and Van Cutsem discuss the implications of recently published data from the phase II ReDOS trial, which evaluated dosing strategies for regorafenib in refractory metastatic colorectal cancer (mCRC).
Earn CME Credit for this activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=CRC
© 2018 Imedex, LLC.